Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br Marinac CR Nelson SH

    2020-08-14


    [28] Marinac CR, Nelson SH, Breen CI, et al. Prolonged nightly fasting and breast cancer prognosis. JAMA Oncol 2016;2:1049e55. [29] Djiogue S, Nwabo Kamdje AH, Vecchio L, et al. Insulin resistance and cancer: the role of insulin and IGFs. Endocr Relat Cancer 2013;20:R1e17. [30] Brower KJ, Aldrich MS, Robinson EA, et al. Insomnia, self-medication, and relapse to alcoholism. Am J Psychiatry 2001;158:399e404. [31] Jung SJ, Shin A, Kang D. Active smoking and exposure to secondhand smoke and their relationship to depressive symptoms in the Korea national health and nutrition examination survey (KNHANES). BMC Public Health 2015;15: 1053.
    [32] Kiss Z, Ghosh PM. Women in cancer thematic review: circadian rhythmicity and the influence of 'clock' E-64d on prostate cancer. Endocr Relat Cancer 2016;23:T123e34.
    [33] Blakeman V, Williams JL, Meng QJ, et al. Circadian clocks and breast cancer. Breast Cancer Res 2016;18:89. [34] O'Brien PL, Karnell LH, Gokhale M, et al. Prescribing of benzodiazepines and opioids to individuals with substance use disorders. Drug Alcohol Depend 2017;178:223e30.
    [35] Schwarz S, Messerschmidt H, Doren M. Psychocosial risk factors for cancer development [in German]. Med Klin (Munich) 2007;102:967e79. [36] Obiora E, Hubbard R, Sanders RD, et al. The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested caseecontrol and survival analysis in a population-based cohort. Thorax 2013;68:163e70.
    [37] Iqbal U, Syed-Abdul S, Nguyen PA, et al. The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested caseecontrol and survival analysis in a population-based cohort. Thorax 2013;68:591e2.
    Contents lists available at ScienceDirect
    Gynecologic Oncology
    Association of chemotherapy and radiotherapy sequence with overall survival in locoregionally advanced endometrial cancer
    Chelain R. Goodman a, , Saleh Hatoum a, Brandon-Luke L. Seagle b, Eric D. Donnelly a, Emma L. Barber b, Shohreh Shahabi b, Daniela E. Matei b, Jonathan B. Strauss a
    a Department of Radiation Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, United States of America
    b Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, United States of America
    • No randomized trial of advanced endometrial cancer has evaluated treatment with chemotherapy (CT) before radiotherapy (RT).
    • Women who received RT after CT had longer survival than those who received RT before CT or either treatment alone.
    • Treatment with multi-agent CT before RT should be considered for inclusion as a treatment arm in future prospective trials.
    Article history:
    Keywords:
    Radiotherapy
    Chemotherapy
    Endometrial cancer 
    Objective. The optimal adjuvant management of women with FIGO Stage III-IVA endometrial cancer (EC) is unclear. While recent prospective data suggest that treatment with pelvic radiotherapy (RT) prior to chemother-apy (CT) is not associated with a survival benefit compared to CT alone, no prospective randomized trial has in-cluded a treatment arm in which CT is given before RT.
    Methods. An observational cohort study was performed on women with FIGO Stage III-IVA Type 1 (grade 1–2, endometrioid) EC who underwent hysterectomy and received multi-agent CT and/or RT from 2004 to 2014 at Commission on Cancer-accredited hospitals. Multivariable parametric accelerated failure time models were per-formed to estimate the association of sequence of adjuvant CT and RT with overall survival (OS) using propensity score-adjusted matched cohorts.
    1. Introduction
    The optimal adjuvant management of stage III-IVA endometrial can-cer (EC) remains a source of debate. Results from recent trials PORTEC-3 and the Gynecology Oncology Group (GOG) 258 suggest minimal
    Corresponding author at: Department of Radiation Oncology, E-64d Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 251 E Huron St, Room LC-178, Chicago, IL 60611, United States of America.
    E-mail address: [email protected] (C.R. Goodman). 
    improvement in overall survival (OS) with combined chemoradiother-apy (CRT) compared to chemotherapy (CT) or pelvic radiotherapy (RT) alone [1,2]. These data do, however, demonstrate the potential complementary roles of both adjuvant therapies: CT in the reduction of distant recurrence and RT in minimizing locoregional recurrence (LRR). A subset analysis of PORTEC-3 demonstrated that Stage III pa-tients treated with CRT experienced longer 5-year (y) progression-free survival (PFS) [1]. No prospective trial has included a treatment arm in which CT is given before RT or sequenced in a “sandwich” fash-ion. This begs the question: should chemotherapy be the first adjuvant